Agilent Technologies Inc. (Santa Clara, California) has agreed to support research by Steven Gross, a faculty member in the Department of Pharmacology at Weill Cornell Medical College (New York, New York), into amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.
Agilent Technologies Inc. (Santa Clara, California) has agreed to support research by Steven Gross, a faculty member in the Department of Pharmacology at Weill Cornell Medical College (New York, New York), into amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. Agilent will provide the latest mass spectrometry technology to support this research, which aims to achieve an understanding of how the most common form of this disease develops in the body.
Gross is an internationally recognized expert in the use of mass spectrometry-based metabolomics. His expertise is in pharmacology and cell biology, particularly in relation to the role of nitric oxide as a signaling molecule. Through the partnership, Agilent will provide two mass spectrometers for Gross’s laboratory.
Sporadic amyotrophic lateral sclerosis (sALS) accounts for about 90 percent of all ALS cases and has no obvious genetic driver. Gross and his collaborators-Giovanni Manfredi, a professor of neuroscience in the Feil Family Brain and Mind Research Institute at Weill Cornell, and Lorenz Studer, director of Sloan Kettering Institute’s Center for Stem Cell Biology-are investigating the molecular underpinnings of this form of ALS. The Agilent tools will assist the investigators in applying a multi-disciplinary-based approach to understanding the roots of this disease. Specifically, accurate-mass spectrometry will enable the researchers to test the hypothesis that fibroblasts express systemic metabolic markers that inform ALS.
New AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
February 10th 2025Scientists from China and Finland have developed an advanced method for detecting cardiovascular drugs in blood using surface-enhanced Raman spectroscopy (SERS) and artificial intelligence (AI). This innovative approach, which employs "molecular hooks" to selectively capture drug molecules, enables rapid and precise analysis, offering a potential advance for real-time clinical diagnostics.
Detection of Microplastics in Bottled Water Using Raman Microspectroscopy
February 10th 2025Spectroscopy sat down with Oskar Hagelskjaer, Founder and CEO of Microplastic Solution, to discuss his latest study whose findings challenge EU Directive 2020/2184 regarding microplastic detection in potable water.
Developing a Handheld Fiber-Optic Tissue Sensing Device for Spine Surgery
February 10th 2025A recent study proposed a compact, cost-effective, handheld fiber-optic device using simplified DRS technology to track the accuracy of pedicle screw placement in spinal fusion procedures. Spectroscopy spoke to Merle Losch, corresponding author for the paper resulting from this study, about the device and the team’s efforts to produce it.